Breast Cancer Research and Treatment

, Volume 138, Issue 2, pp 347–358 | Cite as

A systematic review on topoisomerase 1 inhibition in the treatment of metastatic breast cancer

  • Iben Kümler
  • Nils Brünner
  • Jan Stenvang
  • Eva Balslev
  • Dorte L. Nielsen


Following treatment with anthracyclines and taxanes, few established options exist for the treatment of metastatic breast cancer (MBC). Although the topoisomerase 1 inhibitors irinotecan, etirinotecan, and topotecan have been used in clinical trials on MBC, the drugs have never been introduced as standard treatment for the disease. We performed a systematic review on topoisomerase 1 inhibitors in MBC and found 22 prospective trials and three retrospective ones. No phase III trials were identified. Only one study was randomized, and generally studies were small. Response rates (RR) for irinotecan monotherapy varied from 5 to 23 %, whereas RRs for etirinotecan were 26–32 %. Only four trials on topotecan monotherapy were reported with RRs of 6–31 %. Combination therapy with irinotecan and various chemotherapeutics resulted in RRs ranging from 14 to 64 %, whereas irinotecan combined with biologic agents showed very limited effect. Topotecan was studied in combination with either another chemotherapeutic or a biologic agent in two trials, both studies failing to show any effect of topotecan. The most common grade 3 and 4 adverse events (AE) for irinotecan were neutropenia, diarrhea, and nausea/vomiting. The dosing schedule appears to affect the toxicity profile of the drug. Hematologic AEs are most frequently reported for topotecan. Conclusively, topotecan does not seem to be efficient in the treatment of MBC. Irinotecan seem to be effective in some patients previously treated with anthracyclines and taxanes. RRs of 23 % for irinotecan and 32 % for etirinotecan are comparable to some of the more commonly used treatments for MBC. However, a large proportion of patients do not respond, thus emphasizing the need for a biomarker predictive of response to irinotecan in order to introduce this drug as the standard treatment for MBC.


Metastatic breast cancer Topoisomerase 1 inhibitors Treatment Systematic review 


Conflict of interest

The authors declare that they have no conflict of interest.




  1. 1.
    Brewster AM, Hortobagyi GN, Broglio KR, Kau SW, Santa-Maria CA, Arun B, Buzdar AU, Booser DJ, Valero V, Bondy M, Esteva FJ (2008) Residual risk of breast cancer recurrence 5 years after adjuvant therapy. J Natl Cancer Inst 100(16):1179–1183. doi: 1093/jnci/djn233 PubMedCrossRefGoogle Scholar
  2. 2.
    Cardoso F, Bedard PL, Winer EP, Pagani O, Senkus-Konefka E, Fallowfield LJ, Kyriakides S, Costa A, Cufer T, Albain KS (2009) International guidelines for management of metastatic breast cancer: combination vs. sequential single-agent chemotherapy. J Natl Cancer Inst 101(17):1174–1181. doi: 10.1093/jnci/djp235 PubMedCrossRefGoogle Scholar
  3. 3.
    Roche H, Vahdat LT (2011) Treatment of metastatic breast cancer: second line and beyond. Ann Oncol 22(5):1000–1010. doi: 10.1093/annonc/mdq429 PubMedCrossRefGoogle Scholar
  4. 4.
    Cobleigh MA (2011) Other options in the treatment of advanced breast cancer. Semin Oncol 38(suppl 2):S11–S16. doi: 10.1053/j.seminoncol.2011.04.005 PubMedCrossRefGoogle Scholar
  5. 5.
    Rivera E (2010) Management of metastatic breast cancer: monotherapy options for patients resistant to anthracyclines and taxanes. Am J Clin Oncol 33(2):176–185. doi: 10.1097/COC.0b013e3181931049 PubMedGoogle Scholar
  6. 6.
    Moukharskaya J, Verschraegen C (2012) Topoisomerase 1 inhibitors and cancer therapy. Hematol Oncol Clin North Am 26(3):507–525. doi: 10.1016/j.hoc.2012.03.002 PubMedCrossRefGoogle Scholar
  7. 7.
    Azim HA Jr, Awada A (2012) Clinical development of new formulations of cytotoxics in solid tumors. Curr Opin Oncol 24(3):325–331. doi: 10.1097/CCO.0b013e328351fb29 PubMedCrossRefGoogle Scholar
  8. 8.
    Jameson GS, Hamm JT, Weiss GJ, Alemany C, Anthony S, Basche M, Ramanathan RK, Borad MJ, Tibes R, Cohn A, Hinshaw I, Jotte R, Rosen LS, Hoch U, Eldon MA, Medve R, Schroeder K, White E, Von Hoff DD (2012) A multicenter, phase I, dose-escalation study to assess the safety, tolerability, and pharmacokinetics of etirinotecan pegol in patients with refractory solid tumors. Clin Cancer Res 19(1):268–278. doi: 10.1158/1078-0432.CCR-12-1201 PubMedCrossRefGoogle Scholar
  9. 9.
    Beretta GL, Perego P, Zunino F (2008) Targeting topoisomerase I: molecular mechanisms and cellular determinants of response to topoisomerase I inhibitors. Expert Opin Ther Targets 12(10):1243–1256. doi: 10.1517/14728222.12.10.1243 PubMedCrossRefGoogle Scholar
  10. 10.
    Wang JC (2002) Cellular roles of DNA topoisomerases: a molecular perspective. Nat Rev Mol Cell Biol 3(6):430–440. doi: 10.1038/nrm831nrm831 PubMedCrossRefGoogle Scholar
  11. 11.
    Chabot GG (1997) Clinical pharmacokinetics of irinotecan. Clin Pharmacokinet 33(4):245–259PubMedCrossRefGoogle Scholar
  12. 12.
    Stein A, Arnold D (2012) Oxaliplatin: a review of approved uses. Expert Opin Pharmacother 13(1):125–137. doi: 10.1517/14656566.2012.643870 PubMedCrossRefGoogle Scholar
  13. 13.
    Bittoni A, Maccaroni E, Scartozzi M, Berardi R, Cascinu S (2010) Chemotherapy for locally advanced and metastatic gastric cancer: state of the art and future perspectives. Eur Rev Med Pharmacol Sci 14(4):309–314PubMedGoogle Scholar
  14. 14.
    Gebbia V, Maiello E, Giuliani F, Borsellino N, Arcara C, Colucci G (2010) Irinotecan plus bolus/infusional 5-Fluorouracil and leucovorin in patients with pretreated advanced pancreatic carcinoma: a multicenter experience of the Gruppo Oncologico Italia Meridionale. Am J Clin Oncol 33(5):461–464. doi: 10.1097/COC.0b013e3181b4e3b0 PubMedCrossRefGoogle Scholar
  15. 15.
    Jakobsen JN, Hasselbalch B, Stockhausen MT, Lassen U, Poulsen HS (2011) Irinotecan and bevacizumab in recurrent glioblastoma multiforme. Expert Opin Pharmacother 12(5):825–833. doi: 10.1517/14656566.2011.566558 PubMedCrossRefGoogle Scholar
  16. 16.
    Naumann RW, Coleman RL (2011) Management strategies for recurrent platinum-resistant ovarian cancer. Drugs 71(11):1397–1412. doi: 10.2165/11591720-000000000-000003 PubMedCrossRefGoogle Scholar
  17. 17.
    Hartwell D, Jones J, Loveman E, Harris P, Clegg A, Bird A (2011) Topotecan for relapsed small cell lung cancer: a systematic review and economic evaluation. Cancer Treat Rev 37(3):242–249. doi: 10.1016/j.ctrv.2010.07.005S0305-7372(10)00130-1 PubMedCrossRefGoogle Scholar
  18. 18.
    Lorusso D, Pietragalla A, Mainenti S, Masciullo V, Di Vagno G, Scambia G (2010) Review role of topotecan in gynaecological cancers: current indications and perspectives. Crit Rev Oncol Hematol 74(3):163–174. doi: 10.1016/j.critrevonc.2009.08.001S1040-8428(09)00158-9 PubMedCrossRefGoogle Scholar
  19. 19.
    Fracasso PM, Williams KJ, Chen RC, Picus J, Ma CX, Ellis MJ, Tan BR, Pluard TJ, Adkins DR, Naughton MJ, Rader JS, Arquette MA, Fleshman JW, Creekmore AN, Goodner SA, Wright LP, Guo Z, Ryan CE, Tao Y, Soares EM, Cai SR, Lin L, Dancey J, Rudek MA, McLeod HL, Piwnica-Worms H (2011) A Phase 1 study of UCN-01 in combination with irinotecan in patients with resistant solid tumor malignancies. Cancer Chemother Pharmacol 67(6):1225–1237. doi: 10.1007/s00280-010-1410-1 PubMedCrossRefGoogle Scholar
  20. 20.
    Ikeda H, Koshiba R (2000) A pilot study of irinotecan hydrochloride for metastatic breast cancer–efficacy as a salvage therapy. Gan To Kagaku Ryoho 27(5):723–727PubMedGoogle Scholar
  21. 21.
    Ikeda M, Kurebayashi J, Sonoo H, Oota Y, Fujii S, Shimo T, Miyake A, Seki M, Souda M, Nomura T, Yamamoto Y, Shiiki S, Nakashima K, Tanaka K (2009) Evaluation of irinotecan hydrochloride (CPT-11) and trastuzumab combination therapy as salvage treatment in patients with HER2 overexpressing metastatic breast cancer. Gan To Kagaku Ryoho 36(5):773–777PubMedGoogle Scholar
  22. 22.
    Okubo S, Kurebayashi J, Sonoo H, Hirono M, Nomura N, Udagawa K, Yamamoto Y, Ikeda M, Nakashima K, Tanaka K (2003) Retrospective study on utility of irinotecan hydrochloride in patients with advanced and recurrent breast cancer. Gan To Kagaku Ryoho 30(10):1441–1445PubMedGoogle Scholar
  23. 23.
    Doihara H, Takashima S, Yokoyama N (1994) Four cases of recurrent breast cancer effectively treated by the new antitumor agent, CPT-11 (irinotecan). Gan To Kagaku Ryoho 21(8):1263–1266PubMedGoogle Scholar
  24. 24.
    Murata T, Fujii M, Aoki M, Oda K (2011) A case of spindle cell carcinoma of the breast, in which irinotecan was effective against respiratory failure due to pulmonary metastases. Gan To Kagaku Ryoho 38(3):431–434PubMedGoogle Scholar
  25. 25.
    Wolff AC, O’Neill A, Kennedy MJ, Stewart JA, Gradishar WJ, Lord RS 3rd, Davidson NE, Wood WC (2005) Single-agent topotecan as first-line chemotherapy in women with metastatic breast cancer: final results of eastern cooperative oncology group trial E8193. Clin Breast Cancer 6(4):334–339. doi: 10.3816/CBC.2005.n.037 PubMedCrossRefGoogle Scholar
  26. 26.
    Fleming GF, Kugler JW, Hoffman PC, Ansari R, Bitran JD, Klepsch A, Malone D, Fasanmade AA, Ratain MJ, Vokes EE (1998) Phase II trial of paclitaxel and topotecan with granulocyte colony-stimulating factor support in stage IV breast cancer. J Clin Oncol 16(6):2032–2037PubMedGoogle Scholar
  27. 27.
    Chang H, Han S, Oh D, Im S, Kim T, Bang Y (2009) Combination chemotherapy of irinotecan with fluoropyrimidine in taxane, anthracycline and fluoropyrimidine-pretreated metastatic breast cancer. J Clin Oncol 27 (Suppl):abstract e12003Google Scholar
  28. 28.
    Espinós J, Olier-Garate C, Aramendia JM, Hidalgo OF, Reyna C, De La Cruz S, del Barrio A, Garcia-Foncillas J (2008) Efficacy of the combination of irinotecan and bevacizumab in heavely pretreated metastatic breast cancer. J Clin Oncol 26 (May 20 suppl):abstract 12001Google Scholar
  29. 29.
    Mrozek E, Kolesar J, Young D, Allen J, Villalona-Calero M, Shapiro CL (2008) Phase II study of sequentially administered low-dose mitomycin-C(MMC) and irinotecan (CPT-11) in women with metastatic breast cancer (MBC). Ann Oncol 19(8):1417–1422. doi: 10.1093/annonc/mdn154 PubMedCrossRefGoogle Scholar
  30. 30.
    Vukelja S, O′Shaughnessy J, Campos L, Vahdat J, Blum J, Yardley P, Mainwaring F, Senecal R, Benner R, Denis L, Perez E (2005) Activity of oral irinotecan n metastatic breast cancer patients after prior anthracycline, taxane and capecitabine: phase 2 study results. J Clin Oncol 23(16S):619Google Scholar
  31. 31.
    Tan WW, Hillman DW, Salim M, Northfelt DW, Anderson DM, Stella PJ, Niedringhaus R, Bernath AM, Gamini SS, Palmieri F, Perez EA (2010) N0332 phase 2 trial of weekly irinotecan hydrochloride and docetaxel in refractory metastatic breast cancer: a North Central Cancer Treatment Group (NCCTG) Trial. Ann Oncol 21(3):493–497. doi: 10.1093/annonc/mdp328 PubMedCrossRefGoogle Scholar
  32. 32.
    Lin NU, Eierman W, Greil R, Campone M, Kaufman B, Steplewski K, Lane SR, Zembryki D, Rubin SD, Winer EP (2011) Randomized phase II study of lapatinib plus capecitabine or lapatinib plus topotecan for patients with HER2-positive breast cancer brain metastases. J Neurooncol 105(3):613–620. doi: 10.1007/s11060-011-0629-y PubMedCrossRefGoogle Scholar
  33. 33.
    Hayashi H, Tsurutani J, Satoh T, Masuda N, Okamoto W, Morinaga R, Terashima M, Miyazaki M, Okamoto I, Nishida Y, Tominaga S, Tokunaga Y, Yamaguchi M, Sakamoto J, Nakayama T, Nakagawa K (2011) Phase II study of bi-weekly irinotecan for patients with previously treated HER2-negative metastatic breast cancer: KMBOG0610B. Breast Cancer 6(8):e23849. doi: 10.1007/s12282-011-0316-z Google Scholar
  34. 34.
    Perez EA, Hillman DW, Mailliard JA, Ingle JN, Ryan JM, Fitch TR, Rowland KM, Kardinal CG, Krook JE, Kugler JW, Dakhil SR (2004) Randomized phase II study of two irinotecan schedules for patients with metastatic breast cancer refractory to an anthracycline, a taxane, or both. J Clin Oncol 22(14):2849–2855. doi: 10.1200/JCO.2004.10.047 PubMedCrossRefGoogle Scholar
  35. 35.
    Shigeoka Y, Itoh K, Igarashi T, Ishizawa K, Saeki T, Fujii H, Minami H, Imoto S, Sasaki Y (2001) Clinical effect of irinotecan in advanced and metastatic breast cancer patients previously treated with doxorubicin- and docetaxel-containing regimens. Jpn J Clin Oncol 31(8):370–374PubMedCrossRefGoogle Scholar
  36. 36.
    Garcia AA, Awada A, Chan S, Jerusalem G, Coleman RE, Huizing MT, Mehdi A, O′Reilly SM, Hamm JT, Barrett-Lee PJ, Cocquyt V, Sideras K, Young D, Brown M, Zhao C, Hannah AL, Leung AC, Masuoka LK, Perez EA (2011) Final results of NKTR-102, a topoisomeraseI inhibitor-polymer conjugate in patients with pretreated metastatic breast cancer demonstrating significant antitumor activity. J Clin Oncol 29 (suppl 27):abstract 269Google Scholar
  37. 37.
    Lee KS, Park IH, Nam BH, Ro J (2013) Phase II study of irinotecan plus capecitabine in anthracycline- and taxane-pretreated patients with metastatic breast cancer. Invest New Drugs 31(1):152–159. doi: 10.1007/s10637-012-9824-8 PubMedCrossRefGoogle Scholar
  38. 38.
    O’Connor T, Rustum Y, Levine E, Creaven P (2008) A phase I study of capecitabine and a modulatory dose of irinotecan in metastatic breast cancer. Cancer Chemother Pharmacol 61(1):125–131. doi: 10.1007/s00280-007-0456-1 PubMedCrossRefGoogle Scholar
  39. 39.
    Tanaka M, Furusawa H, Kamada Y, Sagara Y, Anan K, Miyara K, Kai Y, Wakamatsu S, Uga T, Tamura K, Mitsuyama S (2010) Pilot study of irinotecan and S-1 for advanced and metastatic breast cancer. Cancer Res 70(suppl 24)Google Scholar
  40. 40.
    Hobday TJ, Stella PJ, Fitch TR, Jaslowski A, LaPlant B, Ames MM, Goetz MP, Perez EA (2008) NO436: A phase II trial of irinotecan plus cetuximab in patients with metastatic breast cancer and prior anthracycline and/or taxane-containing therapy. J Clin Oncol 26 (May 20 suppl):abstract 1081Google Scholar
  41. 41.
    Ma CX, Ellis MJ, Petroni GR, Lockhart AC, Naughton M, Pluard TJ, Brenin C, Picus J, Creekmore AN, Mwandoro TN, Guo Z, Cai S, Ryan C, Yarde E, Hoog J, Dancey J, Watson M, Piwnica-Worms H, Fracasso PM (2012) Clinical and correlative science results in a phase II study of UCN-01 in combination with irinotecan in recurrent triple-negative breast cancer. J Clin Oncol 30 (suppl):abstract 3047Google Scholar
  42. 42.
    Moulder S, Mita M, Bradley C, Rocha C, Harris L (2010) A phase 1b study to assess the safety and tolerability of the PARP inhibitor iniparib in combination with irinotecan for the treatment of patients with metastatic breast cancer. Presented at SABC:abstract P6-15-01Google Scholar
  43. 43.
    Moulder S, Valkov N, Neuger A, Choi J, Lee JH, Minton S, Munster P, Gump J, Lacevic M, Lush R, Sullivan D (2008) Phase 2 study of gemcitabine and irinotecan in metastatic breast cancer with correlatives to determine topoisomerase I localization as a predictor of response. Cancer 113(10):2646–2654. doi: 10.1002/cncr.23916 PubMedCrossRefGoogle Scholar
  44. 44.
    Von Hoff DD, Jameson GS, Borad MJ, Rosen LS, Utz J, Basche M, Alemany C, Dhar S, Acosta L, Barker T, Walling J, Hamm JT (2008) First phase I trial of NKTR-102 (Peg-Irinotecan) reveals early ecidence of broad anti-tumor activity in three different schedules. In: EORTC-NCI-AACR symposium on “molecular targets and cancer therapeutics” Poster no. 595, GenevaGoogle Scholar
  45. 45.
    Zander SA, Sol W, Greenberger L, Zhang Y, van Tellingen O, Jonkers J, Borst P, Rottenberg S (2012) EZN-2208 (PEG-SN38) overcomes ABCG2-mediated topotecan resistance in BRCA1-deficient mouse mammary tumors. PLoS One 7(9):45248. doi: 10.1371/journal.pone.0045248PONE-D-12-18536 CrossRefGoogle Scholar
  46. 46.
    Frasci G, D’Aiuto G, Thomas R, Comella P, Di Bonito M, Lapenta L, D’Aiuto M, Botti G, Vallone P, De Rosa V, D’Aniello R, Giordano R, Comella G (2005) Biweekly docetaxel-irinotecan treatment with filgrastim support is highly active in antracycline–paclitaxel–refractory breast cancer patients. Oncology 68(4–6):391–397. doi: 10.1159/000086980 PubMedCrossRefGoogle Scholar
  47. 47.
    Stathopoulos GP, Tsavdaridis D, Malamos NA, Rigatos SK, Kosmas C, Pergantas N, Stathopoulos JG, Xynotroulas J (2005) Irinotecan combined with docetaxel in pre-treated metastatic breast cancer patients: a phase II study. Cancer Chemother Pharmacol 56(5):487–491. doi: 10.1007/s00280-005-1006-3 PubMedCrossRefGoogle Scholar
  48. 48.
    Katz A, Hoff PM, Simon SD, Gansl RC, Tabacof J, Abramoff R, Pietrocola M, Smaletz O, Novis Y (2003) Itinotecan and cisplatin in heavily pre-treated metastatic breast cancer patients. Proc Am Soc Clin Oncol 22: abstract 335Google Scholar
  49. 49.
    Levine EG, Cirrincione CT, Szatrowski TP, Canellos G, Norton L, Henderson IC (1999) Phase II trial of topotecan in advanced breast cancer: a Cancer and Leukemia Group B study. Am J Clin Oncol 22(3):218–222PubMedCrossRefGoogle Scholar
  50. 50.
    Mainwaring PN, Nicolson MC, Hickish T, Penson R, Joel S, Slevin M, Smith IE (1997) Continuous infusional topotecan in advanced breast and non-small-cell lung cancer: no evidence of increased efficacy. Br J Cancer 76(12):1636–1639PubMedCrossRefGoogle Scholar
  51. 51.
    Oberhoff C, Kieback DG, Wurstlein R, Deertz H, Sehouli J, van Soest C, Hilfrich J, Mesrogli M, von Minckwitz G, Staab HJ, Schindler AE (2001) Topotecan chemotherapy in patients with breast cancer and brain metastases: results of a pilot study. Onkologie 24(3):256–260PubMedCrossRefGoogle Scholar
  52. 52.
    Cardoso F, Costa A, Norton L, Cameron D, Cufer T, Fallowfield L, Francis P, Gligorov J, Kyriakides S, Lin N, Pagani O, Senkus E, Thomssen C, Aapro M, Bergh J, Di Leo A, El Saghir N, Ganz PA, Gelmon K, Goldhirsch A, Harbeck N, Houssami N, Hudis C, Kaufman B, Leadbeater M, Mayer M, Rodger A, Rugo H, Sacchini V, Sledge G, Van’t Veer L, Viale G, Krop I, Winer E (2012) 1st International consensus guidelines for advanced breast cancer (ABC 1). Breast 21(3):242–252. doi: 10.1016/j.breast.2012.03.003 PubMedCrossRefGoogle Scholar
  53. 53.
    Sledge GW, Neuberg D, Bernardo P, Ingle JN, Martino S, Rowinsky EK, Wood WC (2003) Phase III trial of doxorubicin, paclitaxel, and the combination of doxorubicin and paclitaxel as front-line chemotherapy for metastatic breast cancer: an intergroup trial (E1193). J Clin Oncol 21(4):588–592PubMedCrossRefGoogle Scholar
  54. 54.
    Seidman AD, Berry D, Cirrincione C, Harris L, Muss H, Marcom PK, Gipson G, Burstein H, Lake D, Shapiro CL, Ungaro P, Norton L, Winer E, Hudis C (2008) Randomized phase III trial of weekly compared with every-3-weeks paclitaxel for metastatic breast cancer, with trastuzumab for all HER-2 overexpressors and random assignment to trastuzumab or not in HER-2 nonoverexpressors: final results of Cancer and Leukemia Group B protocol 9840. J Clin Oncol 26(10):1642–1649. doi: 10.1200/JCO.2007.11.6699 PubMedCrossRefGoogle Scholar
  55. 55.
    Ejlertsen B, Mouridsen HT, Langkjer ST, Andersen J, Sjostrom J, Kjaer M (2004) Phase III study of intravenous vinorelbine in combination with epirubicin versus epirubicin alone in patients with advanced breast cancer: a Scandinavian Breast Group Trial (SBG9403). J Clin Oncol 22(12):2313–2320. doi: 10.1200/JCO.2004.11.503 JCO.2004.11.503 [pii]PubMedCrossRefGoogle Scholar
  56. 56.
    Nielsen D, Dombernowsky P, Larsen SK, Hansen OP, Skovsgaard T (2000) Epirubicin or epirubicin and cisplatin as first-line therapy in advanced breast cancer. A phase III study. Cancer Chemother Pharmacol 46(6):459–466PubMedCrossRefGoogle Scholar
  57. 57.
    Albain KS, Nag SM, Calderillo-Ruiz G, Jordaan JP, Llombart AC, Pluzanska A, Rolski J, Melemed AS, Reyes-Vidal JM, Sekhon JS, Simms L, O’Shaughnessy J (2008) Gemcitabine plus paclitaxel versus paclitaxel monotherapy in patients with metastatic breast cancer and prior anthracycline treatment. J Clin Oncol 26(24):3950–3957. doi: 10.1200/JCO.2007.11.9362 PubMedCrossRefGoogle Scholar
  58. 58.
    Blackstein M, Vogel CL, Ambinder R, Cowan J, Iglesias J, Melemed A (2002) Gemcitabine as first-line therapy in patients with metastatic breast cancer: a phase II trial. Oncology 62(1):2–8PubMedCrossRefGoogle Scholar
  59. 59.
    Oshaughnessy JA, Blum J, Moiseyenko V, Jones SE, Miles D, Bell D, Rosso R, Mauriac L, Osterwalder B, Burger HU, Laws S (2001) Randomized, open-label, phase II trial of oral capecitabine (Xeloda) vs. a reference arm of intravenous CMF (cyclophosphamide, methotrexate and 5-fluorouracil) as first-line therapy for advanced/metastatic breast cancer. Ann Oncol 12(9):1247–1254PubMedCrossRefGoogle Scholar
  60. 60.
    Kusama M, Nomizu T, Aogi K, Yoshimoto M, Horikoshi N, Tabei T, Noguchi S, Miura S, Yoshimura N, Kimura M, Toyama K, Shin E (2010) Phase II study of 4-weekly capecitabine monotherapy in advanced/metastatic breast cancer. Breast Cancer 17(4):233–240. doi: 10.1007/s12282-009-0137-5 PubMedCrossRefGoogle Scholar
  61. 61.
    Stockler MR, Harvey VJ, Francis PA, Byrne MJ, Ackland SP, Fitzharris B, Van Hazel G, Wilcken NR, Grimison PS, Nowak AK, Gainford MC, Fong A, Paksec L, Sourjina T, Zannino D, Gebski V, Simes RJ, Forbes JF, Coates AS (2011) Capecitabine versus classical cyclophosphamide, methotrexate, and fluorouracil as first-line chemotherapy for advanced breast cancer. J Clin Oncol 29(34):4498–4504. doi: 10.1200/JCO.2010.33.9101 PubMedCrossRefGoogle Scholar
  62. 62.
    Martin M, Ruiz A, Munoz M, Balil A, Garcia-Mata J, Calvo L, Carrasco E, Mahillo E, Casado A, Garcia-Saenz JA, Escudero MJ, Guillem V, Jara C, Ribelles N, Salas F, Soto C, Morales-Vasquez F, Rodriguez CA, Adrover E, Mel JR (2007) Gemcitabine plus vinorelbine versus vinorelbine monotherapy in patients with metastatic breast cancer previously treated with anthracyclines and taxanes: final results of the phase III Spanish Breast Cancer Research Group (GEICAM) trial. Lancet Oncol 8(3):219–225. doi: 10.1016/S1470-2045(07)70041-4 PubMedCrossRefGoogle Scholar
  63. 63.
    Dumez H, Awada A, Piccart M, Assadourian S, Semiond D, Guetens G, de Boeck G, Maes RA, de Bruijn EA, van Oosterom A (2006) A phase I dose-finding clinical pharmacokinetic study of an oral formulation of irinotecan (CPT-11) administered for 5 days every 3 weeks in patients with advanced solid tumours. Ann Oncol 17(7):1158–1165. doi: 10.1093/annonc/mdl071 PubMedCrossRefGoogle Scholar
  64. 64.
    Kuppens IE, Dansin E, Boot H, Feger C, Assadourian S, Bonneterre ME, Beijnen JH, Schellens JH, Bonneterre J (2006) Dose-finding phase I clinical and pharmacokinetic study of orally administered irinotecan in patients with advanced solid tumors. Clin Cancer Res 12(12):3774–3781. doi: 10.1158/1078-0432.CCR-05-2368 PubMedCrossRefGoogle Scholar
  65. 65.
    Pitot HC, Adjei AA, Reid JM, Sloan JA, Atherton PJ, Rubin J, Alberts SR, Duncan BA, Denis L, Schaaf LJ, Yin D, Sharma A, McGovren P, Miller LL, Erlichman C (2006) A phase I and pharmacokinetic study of a powder-filled capsule formulation of oral irinotecan (CPT-11) given daily for 5 days every 3 weeks in patients with advanced solid tumors. Cancer Chemother Pharmacol 58(2):165–172. doi: 10.1007/s00280-005-0138-9 PubMedCrossRefGoogle Scholar
  66. 66.
    Schoemaker NE, Kuppens IE, Huinink WW, Lefebvre P, Beijnen JH, Assadourian S, Sanderink GJ, Schellens JH (2005) Phase I study of an oral formulation of irinotecan administered daily for 14 days every 3 weeks in patients with advanced solid tumours. Cancer Chemother Pharmacol 55(3):263–270. doi: 10.1007/s00280-004-0874-2 PubMedCrossRefGoogle Scholar
  67. 67.
    Braun MS, Richman SD, Quirke P, Daly C, Adlard JW, Elliott F, Barrett JH, Selby P, Meade AM, Stephens RJ, Parmar MK, Seymour MT (2008) Predictive biomarkers of chemotherapy efficacy in colorectal cancer: results from the UK MRC FOCUS trial. J Clin Oncol 26(16):2690–2698. doi: 10.1200/JCO.2007.15.5580 PubMedCrossRefGoogle Scholar
  68. 68.
    Koopman M, Knijn N, Richman S, Seymour M, Quirke P, van Tinteren H, van Krieken JHJM, Punt CJ, Nagtegaal ID (2009) The correlation between Topoisomerase-I expression and outcome of treatment with capecitabine and irinotecan in advanced colorectal cancer patients treated in the CAIRO study of the Dutch Colorectal Cancer Group. EJC Supplements 7:321–322Google Scholar
  69. 69.
    Romer MU, Jensen NF, Nielsen SL, Muller S, Nielsen KV, Nielsen HJ, Brunner N (2012) TOP1 gene copy numbers in colorectal cancer samples and cell lines and their association to in vitro drug sensitivity. Scand J Gastroenterol 47(1):68–79. doi: 10.3109/00365521.2011.638393 PubMedCrossRefGoogle Scholar
  70. 70.
    Stenvang J, Smid M, Nielsen SL, Timmermans M, Rømer M, Nielsen D, Foekens J, Brünner N, Martens J (2012) Topoisomerase 1 gene copy aberrations in 52 human breast cancer cell lines and association to gene expression. Cancer Res 72(suppl)Google Scholar
  71. 71.
    Stenvang J, Smid M, Nielsen S, Balslev E, Timmerman J, Rømer M, Nygaard S, Christensen I, Nielsen D, Foekens J, Brünner N, Martens J (2012) Topoisomerase 1 gene copy aberration is a frequent finding in clinical breast cancer samples. Cancer Res 72(suppl)Google Scholar
  72. 72.
    Lynch BJ, Bronstein IB, Holden JA (2001) Elevations of DNA topoisomerase I in invasive carcinoma of the breast. Breast J 7(3):176–180PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2013

Authors and Affiliations

  • Iben Kümler
    • 1
  • Nils Brünner
    • 2
  • Jan Stenvang
    • 2
  • Eva Balslev
    • 3
  • Dorte L. Nielsen
    • 1
  1. 1.Department of OncologyHerlev Hospital, University of CopenhagenHerlevDenmark
  2. 2.Department of Veterinary Disease Biology, Faculty of Life SciencesUniversity of CopenhagenFrederiksberg CDenmark
  3. 3.Department of PathologyHerlev Hospital, University of CopenhagenHerlevDenmark

Personalised recommendations